Early intervention strategies in Alzheimer’s disease – II

Current strategies to prevent AD include primary prevention strategies which identify risk reduction, and secondary prevention strategies which are based on early detection of pathophysiological hallmarks and preclinical intervention.⁶ New consensus diagnostic criteria for preclinical AD and identification of at-risk individuals using preclinical biomarkers are important for defining eligible individuals for clinical trials of secondary prevention strategies.⁶ Several studies are currently ongoing to address this need, and to identify the sufficient trial lengths for delaying cognitive decline, and consequently the onset of symptoms due to AD.⁶

References:
1.Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015; 385 (9984): 2255–2263.

2.Rafii MS, Sperling RA, Donohue MC, et al. The AHEAD 3-45 Study: design of a prevention trial for Alzheimer’s disease. Alzheimers Dement 2023; 19 (4): 1227–1233.

3.FDA press release 6 July 2023. Available at: https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval. Accessed August 2023.

4.FDA press release 7 June 2021. Available at: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug. Accessed August 2023.

5.Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease. Nat Rev Dis Primers 2021; 7 (1): 33.

6.Crous-Bou M, Minguillón C, Gramunt N, Molinuevo JL. Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimers Res Ther 2017; 9 (1): 71.